The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing
Open accessAbstract
SUMMARY: Developing interpretive breakpoints for any given organism-drug combination requires integration of the MIC distribution, pharmacokinetic and pharmacodynamic parameters, and the relationship between in vitro activity and outcome from both in vivo and clinical studies. Previously, the Subcommittee for Antifungal Testing of the Clinical and Laboratory Standards Institute (CLSI [formerly National Committee for Clinical Laboratory Standards]) proposed MIC interpretive breakpoints for fluconazole and Candida spp. These breakpoints were considered to be somewhat weak, because the clinical data supporting them came largely from mucosal infections and there were very few infections involving strains with elevated fluconazole MICs. We readdress the issue of fluconazole breakpoints for Candida by using published clinical and microbiologic data to provide further validation of the breakpoints proposed by the CLSI in 1997. We also address interpretive breakpoints for agar disk diffusion testing of fluconazole. The MIC distribution for fluconazole was determined with a collection of 13,338 clinical isolates. The overall MIC at which 90% of the isolates were inhibited was 8 μg/ml: 91% were susceptible (S) at a MIC of ≤8 μg/ml and 3% were resistant (R) (MIC ≥ 64 μg/ml). Similar results were obtained for 2,190 isolates from randomized clinical trials. Analysis of available data for 1,295 patient-episode-isolate events (692 represented mucosal infections and 603 represented invasive infections) from 12 published clinical studies demonstrated an overall success rate of 77%, including 85% for those episodes in which the fluconazole MIC was ≤8 μg/ml, 67% for those episodes in which the MIC was 16 to 32 μg/ml, and 42% for those episodes with resistant (MIC ≥ 64 μg/ml) isolates. Pharmacodynamic analysis demonstrated a strong relationship between MIC, fluconazole dose, and outcome. A dose/MIC ratio of ∼25 was supportive of the following susceptibility breakpoints for fluconazole and Candida spp.: S, MIC ≤ 8 μg/ml; susceptible-dose dependent (SDD), MIC = 16 to 32 μg/ml; R, MIC ≥ 64 μg/ml. The corresponding disk test breakpoints are as follows: S, ≥19 mm; SDD, 15 to 18 mm; R, ≤14 mm.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Ghannoum, M. A., & Rice, L. B. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.4.501 · Cited by 1,785
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · cited 7×
“, 800 mg/day) are recommended if fluconazole is used to treat infections with this species (59).”
BackgroundInfluentialClinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Self-citationCurrent and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Self-citationRex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Self-citationRex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Self-citationPappas, P. G., Rex, J. H., Lee, J., Hamill, R. J., Larsen, R. A., Powderly, W., Kauffman, C. A., Hyslop, N., Mangino, J. E., Chapman, S., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/376906 · Cited by 845
Hospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Grant, S. M., & Clissold, S. P. (1990) · Drugs · doi:10.2165/00003495-199039060-00006 · Cited by 661
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Sanglard, D., Ischer, F., Monod, M., & Bille, J. (1997) · Microbiology · doi:10.1099/00221287-143-2-405 · Cited by 587
Pfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521
Self-citationAntifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauffman, C. A., Cleary, J., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.10.3149-3154.2003 · Cited by 498
Rex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
History of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 475
Sanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Self-citationAntifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444
Self-citationPfaller, M. A., & Diekema, D. J. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.t01-1-00844.x · Cited by 423
Self-citationDevelopment of in vitro susceptibility testing criteria and quality control parameters
Novick, W. J. (1989) · Clinical Microbiology Newsletter · doi:10.1016/0196-4399(89)90068-8 · Cited by 407
Sanglard, D., Ischer, F., Monod, M., & Bille, J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.10.2300 · Cited by 402
Rees, J. R., Pinner, R. W., Hajjeh, R. A., Brandt, M. E., & Reingold, A. L. (1998) · Clinical Infectious Diseases · doi:10.1093/clinids/27.5.1138 · Cited by 397
Diekema, D. J., Messer, S. A., Brueggemann, A. B., Coffman, S. L., Doern, G. V., Herwaldt, L. A., & Pfaller, M. A. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1298-1302.2002 · Cited by 385
Self-citationThe direct cost and incidence of systemic fungal infections
Wilson, L. S., Reyes, C. M., Stolpman, M., Speckman, J., Allen, K., & Beney, J. (2002) · Value in Health · doi:10.1046/j.1524-4733.2002.51108.x · Cited by 374
Has antifungal susceptibility testing come of age
Rex, J. H., & Pfaller, M. A. (2002) · Clinical Infectious Diseases · doi:10.1086/342384 · Cited by 361
Self-citationSanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337
Pfaller, M. A., Diekema, D. J., Jones, R. N., Messer, S. A., & Hollis, R. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.3.852-856.2002 · Cited by 331
Self-citationSanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319
Livermore, D. M. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1465-0691.2004.1004.x · Cited by 314
Rex, J. H., Pfaller, M. A., Barry, A. L., Nelson, P. W., & Webb, C. D. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.40 · Cited by 301
Self-citationWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1488 · Cited by 292
Antifungal Resistance in Pathogenic Fungi
Perea, S., & Patterson, T. F. (2002) · Clinical Infectious Diseases · doi:10.1086/344058 · Cited by 289
Redding, S., Smith, J., Farinacci, G., Rinaldi, M., Fothergill, A., Rhine-Chalberg, J., & Pfaller, M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.2.240 · Cited by 269
Self-citationPfaller, M. A., & Diekema, D. J. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.10.3551-3557.2002 · Cited by 269
Self-citationPfaller, M. A., Diekema, D. J., Rex, J. H., Espinel-Ingroff, A., Johnson, E. M., Andes, D., Chaturvedi, V., Ghannoum, M. A., Odds, F. C., Rinaldi, M. G., et al. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.819-826.2006 · Cited by 258
Self-citationViudes, A., Pemán, J., Cantón, E., Úbeda, P., López-Ribot, J., & Gobernado, M. (2002) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-002-0822-1 · Cited by 250
Klepser, M. E., Wolfe, E. J., Jones, R. N., Nightingale, C. H., & Pfaller, M. A. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1392 · Cited by 245
Self-citationPfaller, M. A., Messer, S. A., Boyken, L., Hollis, R. J., Rice, C., Tendolkar, S., & Diekema, D. J. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2003.09.008 · Cited by 234
Self-citationPfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., & Diekema, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1723-1727.2002 · Cited by 232
Self-citationPfaller, M. A., Diekema, D. J., Rinaldi, M. G., Barnes, R., Hu, B., Veselov, A. V., Tiraboschi, N., Nagy, E., & Gibbs, D. L. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.12.5848-5859.2005 · Cited by 228
Self-citationNolte, F. S., Parkinson, T., Falconer, D. J., Dix, S., Williams, J., Gilmore, C., Geller, R., & Wingard, J. R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.1.196 · Cited by 219
Mechanism of Fluconazole Resistance in Candida krusei
Orozco, A. S., Higginbotham, L. M., Hitchcock, C. A., Parkinson, T., Falconer, D., Ibrahim, A. S., Ghannoum, M. A., & Filler, S. G. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2645 · Cited by 218
Lopez-Ribot, J. L., McAtee, R. K., Lee, L. N., Kirkpatrick, W. R., White, T. C., Sanglard, D., & Patterson, T. F. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2932 · Cited by 210
Susceptibility Tests of Anaerobic Bacteria: Statistical and Clinical Considerations
Metzler, C. M., & DeHaan, R. M. (1974) · Journal of Infectious Diseases · doi:10.1093/infdis/130.6.588 · Cited by 196
Andes, D., & van Ogtrop, M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2116 · Cited by 192
Ostrosky-Zeichner, L., Kontoyiannis, D., Raffalli, J., Mullane, K. M., Vazquez, J., Anaissie, E. J., Lipton, J., Jacobs, P., Rensburg, J. H. J., Rex, J. H., et al. (2005) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-005-0024-8 · Cited by 189
Increasing Incidence of Candidemia: Results from a 20-Year Nationwide Study in Iceland
Ásmundsdóttir, L. R., Erlendsdóttir, H., & Gottfredsson, M. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.9.3489-3492.2002 · Cited by 188
Pfaller, M. A., Diekema, D. J., Messer, S. A., Boyken, L., & Hollis, R. J. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.4.1440-1446.2003 · Cited by 185
Self-citationActivity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo
Rogers, T. E., & Galgiani, J. N. (1986) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.30.3.418 · Cited by 184
Pfaller, M. A., Messer, S. A., Boyken, L., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.7.3142-3146.2004 · Cited by 182
Self-citationClancy, C. J., Yu, V. L., Morris, A. J., Snydman, D. R., & Nguyen, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3171-3177.2005 · Cited by 176
In Vivo Pharmacodynamics of Antifungal Drugs in Treatment of Candidiasis
Andes, D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1179-1186.2003 · Cited by 169
Marr, K. A., Lyons, C. N., Rustad, T., Bowden, R. A., & White, T. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2584 · Cited by 166 · cited 2×
“as well as from patients with invasive disease (44, 52).”
BackgroundClinical pharmacology of antifungal compounds
Groll, A. H., Gea‐Banacloche, J., Glasmacher, A., Just‐Nübling, G., Maschmeyer, G., & Walsh, T. J. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(02)00068-5 · Cited by 165
Arthington-Skaggs, B. A., Lee-Yang, W., Ciblak, M. A., Frade, J. P., Brandt, M. E., Hajjeh, R. A., Harrison, L. H., Sofair, A. N., & Warnock, A. D. W. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2477-2481.2002 · Cited by 158
Pharmacodynamics of fluconazole in a murine model of systemic candidiasis
Louie, A., Drusano, G. L., Banerjee, P., Liu, Q.-F., Liu, W., Kaw, P., Shayegani, M., Taber, H., & Miller, M. H. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.5.1105 · Cited by 154
Cameron, M. L., Schell, W. A., Bruch, S., Bartlett, J. A., Waskin, H. A., & Perfect, J. R. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.11.2449 · Cited by 152
Safety, Plasma Concentrations, and Efficacy of High-Dose Fluconazole in Invasive Mold Infections
Anaissie, E. J., Kontoyiannis, D. P., Huls, C. E., Vartivarian, S. E., Karl, C., Prince, R. A., Bosso, J. A., & Bodey, G. P. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/172.2.599 · Cited by 147
Antoniadou, A., Torres, H. A., Lewis, R. E., Thornby, J. A., Bodey, G. P., Tarrand, J. P., Han, X.-Y., Rolston, K. V. I., Safdar, A., RAAD, I. I., et al. (2003) · Medicine · doi:10.1097/01.md.0000091182.93122.8e · Cited by 140
St-Germain, G., Laverdière, M., Pelletier, R., Bourgault, A.-M., Libman, M., Lemieux, C., & Noël, G. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.3.949-953.2001 · Cited by 134
Voriconazole Salvage Treatment of Invasive Candidiasis
Ostrosky-Zeichner, L. L., Lashof, A. M. L. O., Kullberg, B. J., & Rex, J. H. (2003) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-003-1014-3 · Cited by 134
Cuenca‐Estrella, M., Rodríguez-Pardo, D., Almirante, B., Morgan, J., Planes, A. M., Almela, M., Mensa, J., Sánchez, F., Ayats, J., Giménez, M., et al. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh548 · Cited by 133
Barry, A. L., Pfaller, M. A., Rennie, R. P., FUCHS, P. C., & Brown, S. D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1781-1784.2002 · Cited by 114
Self-citationEstimating the Cost of Nosocomial Candidemia in the United States
Miller, L. G., Hajjeh, R. A., & Edwards, J. E. (2001) · Clinical Infectious Diseases · doi:10.1086/319613 · Cited by 109 · cited 2×
“Although much of this cost can be attributed to length of stay in hospital, the cost of antifungal therapy, especially the newer lipid formulations of amphotericin B, the echinocandins, and the extended-spectrum triazoles, is not inconsequential (41, 46, 60, 111).”
BackgroundBorst, A., Raimer, M. T., Warnock, D. W., Morrison, C. J., & Arthington, B. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.783-787.2005 · Cited by 109
Hsueh, P., Lau, Y.-J., Chuang, Y.-C., Wan, J.-H., Huang, W.-K., Shyr, J.-M., Yan, J.-J., Yu, K.-W., Wu, J.-J., Ko, W., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.512-517.2005 · Cited by 107
Treatment of Candida albicans fungaemia with fluconazole
Graninger, W., Presteril, E., Schneeweiß, B., Teleky, B. K., & Georgopoulos, A. P. (1993) · Journal of Infection · doi:10.1016/0163-4453(93)92761-k · Cited by 99
The role of antifungal susceptibility testing in the therapy of candidiasis
Hospenthal, D. R., Murray, C. K., & Rinaldi, M. G. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2003.10.003 · Cited by 98
Hazen, K. C., Baron, E. J., Colombo, A. L., Girmenia, C., Sánchez-Sousa, A., del Palacio, A., de BEDOUT, C., & Gibbs, D. L. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.12.5623-5632.2003 · Cited by 96
Lopez-Ribot, J. L., McAtee, R. K., Perea, S. H., Kirkpatrick, W. R., Rinaldi, M. G., & Patterson, T. F. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.7.1621 · Cited by 94
Pfaller, M. A., Boyken, L. B., Messer, S. A., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5208-5213.2005 · Cited by 90
Self-citationChen, Y., Chang, S.-C., Luh, K.-T., & Hsieh, W. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg275 · Cited by 86
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.8.3807-3810.2005 · Cited by 83
Self-citationLee, S.-C., Fung, C., Huang, J., Tsai, C.-J., Chen, K.-S., Chen, H.-Y., Lee, N., See, L., & Wb, S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2715-2718.2000 · Cited by 81
Rodrı́guez-Tudela, J. L., MartinezSuárez, J., Dronda, F., Laguna, F., Cháves, F., & Valencia, E. (1995) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/35.6.793 · Cited by 76
Van t Wout, J. W., Mattie, H., & van Furth, R. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.2.147 · Cited by 72
Pfaller, M. A., & Jones, R. N. (2006) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2006-130-767-paoaaa · Cited by 70
Self-citationPfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.7.3137-3141.2004 · Cited by 66
Self-citationRevankar, S. G., Dib, O. P., Kirkpatrick, W. R., McAtee, R. K., Fothergill, A. W., Rinaldi, M. G., Redding, S. W., & Patterson, T. F. (1998) · Clinical Infectious Diseases · doi:10.1086/513950 · Cited by 66
Antifungal susceptibilities of Candida spp. isolated from blood in Spain and Argentina, 1996-1999
Cuenca‐Estrella, M., Rodero, L., García‐Effrón, G., & Rodriguez-Tudela, J. L. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkf060 · Cited by 65
Tortorano, A. M., Rigoni, A. L., Biraghi, E., Prigitano, A., & Viviani, M. A. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg393 · Cited by 62
Kartsonis, N. A., Saah, A., Lipka, C. J., Taylor, A., & Sable, C. A. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh179 · Cited by 61
Fujihara, N., Saito, T., Kudo, T., Iinuma, Y., Ichiyama, S., & Takakura, S. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1128-2 · Cited by 58
Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans☆
Burgess, D. S., Hastings, R. W., Summers, K. K., Hardin, T. C., & Rinaldi, M. G. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00097-8 · Cited by 57
Pfaller, M. A., Hazen, K. C., Messer, S. A., Boyken, L. B., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.8.3607-3612.2004 · Cited by 55
Self-citationChryssanthou, E. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.11.4181-4183.2001 · Cited by 51
Cuenca‐Estrella, M., Dı́az-Guerra, T. M., Mellado, E., Monz�n, A., & Rodr�guez-Tudela, J. L. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050313 · Cited by 45
Candida infections: outcome and attributable ICU costs in critically ill patients
Pelz, R. K., Lipsett, P. A., Swoboda, S. M., Diener-West, M., Powe, N. R., Brower, R. G., Perl, T. M., Hammond, J. M., & Hendrix, C. W. (2000) · Journal of Intensive Care Medicine · doi:10.1046/j.1525-1489.2000.00255.x · Cited by 45
Hsueh, P., Teng, L., Yang, P., Ho, S., & Luh, K. (2002) · Microbial Drug Resistance · doi:10.1089/10766290260469570 · Cited by 41
Antifungal Susceptibility Testing Methods
Pfaller, M. A. (2005) · Current Drug Targets · doi:10.2174/138945005774912708 · Cited by 39
Self-citationHigh-Dose Fluconazole Therapy in Patients with Severe Fungal Infections
Voss, A., & Pauw, B. E. D. (1999) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960050252 · Cited by 38
CHROMagar Candida Medium for Direct Susceptibility Testing of Yeast from Blood Cultures
Tan, G. L., & Peterson, E. M. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.4.1727-1731.2005 · Cited by 32
Brown, S. D., & Traczewski, M. M. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.01732-06 · Cited by 31
Walmsley, S. L., King, S., McGeer, A., Ye, Y., & Richardson, S. E. (2001) · Clinical Infectious Diseases · doi:10.1086/320517 · Cited by 29
Baddley, J. W., Patel, M., Jones, M., Cloud, G. A., Smith, A. C., & Moser, S. A. (2004) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2004.06.004 · Cited by 29
Clinical pharmacodynamics of antifungals
Andes, D. R. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00063-1 · Cited by 29
Hadley, S., Martinez, J. A., McDermott, L., Rapino, B., & Snydman, D. R. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/49.2.415 · Cited by 29
Arıkan, S., Akova, M., Hayran, M., Özdemir, O., Erman, M., Gür, D., & Ünal, S. (1998) · Clinical Infectious Diseases · doi:10.1086/513927 · Cited by 28
ANTIFUNGAL SUSCEPTIBILITIES OF CANDIDA SPP. ISOLATED FROM BLOOD IN SPAIN AND ARGENTINA
Estrella, M. C., & Rodero, L. (2002) · Cited by 23
Barry, A. L., Billé, J., Brown, S. D., Ellis, D., Meis, J. F. G. M., Pfaller, M. A., Rennie, R. P., Rinaldi, M. G., Rogers, T. R., & Traczewski, M. M. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.7.3410-3412.2003 · Cited by 23
Self-citationCartledge, J. D., Midgley, J., Petrou, M. A., Shanson, D. C., & Gazzard, B. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.4.517 · Cited by 22
Muñóz, P., Fernández-Turégano, C. P., Alcalá, L., Rodríguez‐Créixems, M., Peláez, T., & Bouza, E. (2002) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00432-7 · Cited by 20
Lortholary, O., Charlemagne, A., Bastides, F., Chevalier, P., Datry, A., Gonzalves, M.-F., Michel, G., Tilleul, P., Veber, B., & Herbrecht, R. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh348 · Cited by 16
Wong-Beringera, A., Hindler, J. F., Brankovic, L., Muehlbauer, L., & Steele‐Moore, L. (2001) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(00)00209-1 · Cited by 14
Lacassin, F., Damond, F., Chochillon, C., Longuet, P., Bras, J. L., Vildé, J., & Leport, C. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.8.1961 · Cited by 13
Antifungal susceptibility testing in teaching hospitals
Pai, M. P., & Pendland, S. L. (2003) · Annals of Pharmacotherapy · doi:10.1177/106002800303700205 · Cited by 11 · cited 1×
“However, routine use of antifungal susceptibility testing has been relatively uncommon, and its clinical utility is often limited by delays in the availability of results (9, 28, 31, 57, 59).”
Background
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Self-citationPappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
Pfaller, M. A. (2012) · The American Journal of Medicine · doi:10.1016/j.amjmed.2011.11.001 · Cited by 903
Self-citationEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Self-citation
Metadata
- Authors
- Pfaller, M. A., Diekema, D. J., & Sheehan, D. J.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2006-04
- Volume
- 19
- Issue
- 2
- Pages
- 435-447
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2127333071
- Cited by
- 295
- References
- 112
- FWCI
- 16.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.